ArticleFrontiers in nutrition2026
Development and validation of a novel prognostic model for gastric signet ring cell carcinoma based on inflammation-nutrition indicators.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gastric signet-ring cell carcinoma (GSRCC) is a highly aggressive subtype of gastric cancer with poor prognosis. Existing prognostic models lack integrated analysis of systemic inflammation and nutritional status. This study aimed to develop and validate a prognostic model incorporating inflammatory and nutritional indicators to enhance individualized clinical management in GSRCC patients. Methods: A total of 604 GSRCC patients who underwent curative surgery between 2014 and 2018 were retrospectively analyzed and divided into training ( Results: X-tile analysis determined optimal cut-off values for inflammation and nutrition markers. Multivariate analysis identified age ≥60 years, upper tumor location, T4 stage, N2-N3 stage, lymphocyte-to-CRP ratio (LCR) ≥ 8,785.7, and geriatric nutritional risk index (GNRI) ≥ 112.9 as independent predictors of overall survival (all Conclusions: This study developed and validated a novel GSRCC prognostic nomogram integrating inflammatory and nutritional indicators, offering improved discrimination and clinical utility. It provides a practical tool for precise risk stratification and personalized management of GSRCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.